Corvus Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: CRVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
10.52+0.31 (+3.04%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Corvus Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Corvus Pharmaceuticals generated -$15.4 million of operating cash flow and spent $582,000 on capital expenditures. That left free cash flow of -$16.0 million.
Summary generated from market data by MetaCap's automated system. Methodology
Corvus Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -17.96M | -13.69M | -12.32M | -10.16M | -8.00M | 15.19M | -12.11M | -40.22M | -4.26M | -5.70M | -6.65M | -6.00M |
| Net Income growth (YoY) | — | -190.12% | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 34.00K | 29.00K | 26.00K | 28.00K | 29.00K | 22.00K | 20.00K | 21.00K | 21.00K | 23.00K | 28.00K | 30.00K |
| Stock-Based Compensation | 2.61M | 2.65M | 1.57M | 1.25M | 1.26M | 1.25M | 813.00K | 733.00K | 768.00K | 689.00K | 572.00K | 546.00K |
| Change in Working Capital | -3.19M | 444.00K | 313.00K | -1.10M | 1.74M | -106.00K | -459.00K | 537.00K | -676.00K | 168.00K | 255.00K | -716.00K |
| Operating Cash Flow | -15.40M | -10.37M | -9.19M | -9.57M | -5.78M | -8.26M | -8.46M | -6.32M | -5.48M | -5.16M | -5.17M | -5.43M |
| Capital Expenditures | -582.00K | -91.00K | -25.00K | 0 | -113.00K | -36.00K | — | — | — | — | 0 | 0 |
| Investing Cash Flow | -5.96M | -144.85M | 10.88M | -2.62M | -20.30M | 4.24M | -6.08M | -3.89M | -17.50M | -7.00K | -2.32M | 17.55M |
| Financing Cash Flow | 166.00K | 190.75M | 20.00K | 360.00K | 35.77M | 279.00K | 18.61M | 50.00K | — | — | 0 | 335.00K |
| Net Change in Cash | -21.20M | 35.53M | 1.71M | -11.82M | 9.69M | -3.74M | 4.06M | -10.16M | 7.38M | -5.16M | -7.49M | 12.45M |
| Free Cash Flow | -15.98M | -10.46M | -9.22M | -9.57M | -5.89M | -8.30M | -8.46M | -6.32M | -5.48M | -5.16M | -5.17M | -5.43M |
This table shows 12 quarterly periods of Corvus Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CRVS's reporting calendar. What is a cash flow statement?